Keryx Biopharmaceuticals (KERX) has risen sharply, recording gains of 8.24% in the past 4 weeks. However, the stock has corrected -0.81% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 4.72% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 2.6% and the 50-Day Moving Average is 13.59%. Keryx Biopharmaceuticals Inc. is up 35.29% in the last 3-month period. Year-to-Date the stock performance stands at 45.74%.
Keryx Biopharmaceuticals (NASDAQ:KERX): The stock was completely flat for the day, closing at $7.36 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $7.37, the stock touched an intraday high of $7.46 and a low of $7.25. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $7.36. The total trading volume on Friday was 1,225,535.
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the United States Food and Drug Administration (FDA), for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxias pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT).